Mereo BioPharma Group plc

Mereo BioPharma Group plcverified

MREO

Price:

$3.355

Market Cap:

$519.13M

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-64...[Read more]

Industry

Biotechnology

IPO Date

2019-04-24

Stock Exchange

NASDAQ

Ticker

MREO

The ROE as of December 2024 (TTM) for Mereo BioPharma Group plc (MREO) is -69.11%

According to Mereo BioPharma Group plc’s latest financial reports and current stock price. The company's current ROE is -69.11%. This represents a change of 299.93% compared to the average of -17.28% of the last 4 quarters.

Mereo BioPharma Group plc (MREO) Historical ROE (quarterly & annually)

How has MREO ROE performed in the past?

The mean historical ROE of Mereo BioPharma Group plc over the last ten years is 79.07%. The current -69.11% ROE has changed -187.40% with respect to the historical average. Over the past ten years (40 quarters), MREO's ROE was at its highest in in the December 2020 quarter at 340.23%. The ROE was at its lowest in in the June 2020 quarter at -257.03%.

Quarterly (TTM)
Annual

Average

79.07%

Median

-55.27%

Minimum

-97.74%

Maximum

1.09%

Mereo BioPharma Group plc (MREO) ROE by Quarter and Year

Discovering the peaks and valleys of Mereo BioPharma Group plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 73.35%

Maximum Annual ROE = 1.09%

Minimum Annual Increase = -Infinity%

Minimum Annual ROE = -97.74%

Quarterly (TTM)
Annual
YearROEChange
2023-58.31%5.49%
2022-55.27%-482.25%
202114.46%-98.68%
20201.09%-1362.73%
2019-86.56%-11.44%
2018-97.74%57.40%
2017-62.09%73.35%
2016-35.82%-Infinity%

Mereo BioPharma Group plc (MREO) Average ROE

How has MREO ROE performed in the past?

The current ROE of Mereo BioPharma Group plc (MREO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-33.04%

5-year avg

181.46%

10-year avg

79.07%

Mereo BioPharma Group plc (MREO) ROE vs. Peers

How is MREO’s ROE compared to its peers?

Mereo BioPharma Group plc’s ROE is greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Elevation Oncology, Inc. (-59.73%), greater than Hepion Pharmaceuticals, Inc. (-505.74%),

Build a custom stock screener for Mereo BioPharma Group plc (MREO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mereo BioPharma Group plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mereo BioPharma Group plc (MREO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mereo BioPharma Group plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Mereo BioPharma Group plc's ROE?

How is the ROE calculated for Mereo BioPharma Group plc (MREO)?

What is the highest ROE for Mereo BioPharma Group plc (MREO)?

What is the 3-year average ROE for Mereo BioPharma Group plc (MREO)?

What is the 5-year average ROE for Mereo BioPharma Group plc (MREO)?

How does the current ROE for Mereo BioPharma Group plc (MREO) compare to its historical average?